KORU Medical Systems, Inc.

KORU Medical Systems, Inc. is a medical technology company dedicated to developing, manufacturing, and commercializing innovative and patient-centric large volume subcutaneous infusion solutions. The company's mission is to empower patients with the freedom to live fully by providing infusion pumps and accessories that improve their quality of life. Founded in 1980, KORU Medical Systems is headquartered in Mahwah, New Jersey, USA.

KORU Medical Systems' primary product offering is the Freedom Syringe Infusion System, which includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets™. These products are designed for the subcutaneous drug delivery market, particularly for patients managing chronic illnesses such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). The company also offers Pharma Service and Clinical Trials, providing products for biopharmaceutical companies in feasibility and clinical trials, and customizing the Freedom System for various drug categories.

In recent leadership news, Linda Tharby, the current President and CEO, is set to retire on June 30, 2026, and will be succeeded by Adam Kalbermatten, currently Chief Commercial Officer, effective July 1, 2026. Under Tharby's leadership, KORU Medical Systems doubled its recurring patient base to over 55,000 patients and expanded its international footprint. The company announced EU MDR Certification for its Freedom60® Infusion Pump with Prefilled Syringe Compatibility in March 2026 and reported strong financial performance for full-year 2025, including 22% revenue growth and positive adjusted EBITDA.